# ALKEM (ALKEM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/alkem

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹5,356
- Change: +0.14%
- As of: 2026-09-18
- 1D return: +2.21%
- 5D return: +6.39%
- 1M return: +1.23%
- Latest complete quarter: fy26_q4

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Alkem Laboratories is trading at ₹5466.5, with a mixed technical stance across different timeframes. The daily timeframe shows a bullish trend, with the price above key moving averages like the 20-day Exponential Moving Average (EMA) at ₹5285.68 and the 50-day Simple Moving Average (SMA) at ₹5459.43, and the Supertrend indicator also signaling bullishness. However, the weekly timeframe presents a bearish Supertrend direction, with the price below the weekly Supertrend level of ₹5908.05, indicating potential short-term weakness despite the daily bullish signals. The monthly timeframe aligns with the daily trend, showing a bullish Supertrend and the price above the 20-day EMA (₹5385.95).

Recent activity includes unusual upward price movements on September 18th (weekly, +2%) and September 17th (daily, +3%) with high intraday range, and high participation with no clear direction on September 16th. Active monthly patterns include a "Hammer" and a "Harami," which can sometimes signal reversals. The stock is currently positioned around the middle of its 252-day range (47%) and 50-day range (50%).

Nearest support is observed around ₹5419.17, approximately 0.87% below the current price. Resistance is noted at ₹5489.83, about 0.43% higher. The stock exhibits an annualized volatility of 23% and a current drawdown of -7%. Key watch conditions include monitoring the price action relative to the nearest support and resistance levels, and observing if the weekly bearish Supertrend signal persists or if the daily bullish trend gains further traction.

- Current price as of September 18, 2026: ₹5466.5.
- Daily timeframe shows a bullish trend with price above key moving averages and Supertrend.
- Weekly timeframe indicates a bearish Supertrend signal, contrasting with the daily trend.
- Nearest support level identified at ₹5419.17 (approx. 0.87% below current price).
- Nearest resistance level identified at ₹5489.83 (approx. 0.43% above current price).

- Hammer
- Harami
- Morning Star
- Doji
- Inside Bar
- Bearish Engulfing Reversal

### News Context

Alkem Laboratories saw its stock price increase by 2.36% on September 17, 2026, reaching ₹5,297 on the NSE. This rise occurred as the broader Nifty Pharma Index also gained 1.66% on the same day, snapping a five-day losing streak. Earlier in the week, on September 16, 2026, Alkem Laboratories announced the launch of its new epilepsy medication, NeuCeno (cenobamate), in India. The drug is available for adult patients experiencing partial-onset seizures in various strengths. Despite the recent stock uptick, the company's shares have experienced a 3.33% decline over the past year, contrasting with a 8.21% drop in the NIFTY and a more significant 17.44% decrease in the Nifty Pharma index during the same period.

- Alkem Laboratories stock rose 2.36% to ₹5,297 on September 17, 2026.
- The Nifty Pharma Index increased by 1.66% on September 17, 2026.
- Alkem Laboratories launched NeuCeno (cenobamate) for epilepsy treatment in India on September 16, 2026.
- The company's stock is down 3.33% over the last year, compared to the NIFTY's 8.21% drop and the Nifty Pharma index's 17.44% decline.

- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Alkem Laboratories Ltd spurts 2.36%
- Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India
- Benchmarks recover after recent sell-off; Nifty ends above 23,200

### What Changed

As of September 18, 2026, Alkem Laboratories (NSE: ALKEM) experienced a price increase, closing at ₹5466.5 compared to its previous price of ₹5348.5. This movement occurred within a broader market context where the Nifty Pharma Index saw a rise of 1.66%. No new filings or specific news directly impacting Alkem Laboratories were reported in the recent developments.

- On 2026-09-18, Alkem Laboratories' stock closed at ₹5466.5, up from ₹5348.5.
- The Nifty Pharma Index rose by 1.66%.
- No new corporate filings were reported for Alkem Laboratories.

- Quick Wrap: Nifty Pharma Index rises 1.66%

### Official Filings

Alkem Laboratories Limited has announced the launch of two new products, expanding its pharmaceutical offerings. On September 16, 2026, the company introduced NeuCeno (cenobamate) in India, an oral therapy for partial-onset seizures in adult patients. This launch marks the first availability of cenobamate in the Indian market. Separately, on September 8, 2026, Alkem launched Renocia Exo™, described as India's first patented Ginsenoside Exosome-based hair growth serum, aimed at hair loss management. These product launches contribute to the company's dermatology and neurology portfolios.

In terms of leadership, Alkem appointed Dr. Shubhadeep Sinha to a senior management position, effective September 15, 2026. Dr. Sinha brings over 25 years of experience in areas including clinical development and regulatory affairs. The company also held its 52nd Annual General Meeting on August 27, 2026, where shareholders approved all resolutions, including the adoption of financial statements for the fiscal year ended March 31, 2026, and the re-appointment of directors Sandeep Singh, Sarvesh Singh, and Madhurima Singh. Additionally, shareholders approved a Scheme of Amalgamation with Adroit Biomed Limited on August 17, 2026, with 99.9999% of votes in favor.

- On September 16, 2026, Alkem Laboratories Limited launched NeuCeno (cenobamate) for partial-onset seizures in adults, marking its India debut.
- On September 8, 2026, the company launched Renocia Exo™, a patented Ginsenoside Exosome-based hair growth serum.
- Dr. Shubhadeep Sinha was appointed to a senior management position effective September 15, 2026.
- On August 27, 2026, Alkem's 52nd Annual General Meeting saw shareholders approve all resolutions, including financial statements for the year ended March 31, 2026, and director re-appointments.
- On August 17, 2026, shareholders approved the Scheme of Amalgamation with Adroit Biomed Limited with 99.9999% of votes in favor.

- Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.". |SUBJECT: Press Release
- ALKEM: Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the company w.e.f. September 15, 2026. |SUBJECT: Appointment
- ALKEM LABORATORIES LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA
- Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum". |SUBJECT: Press Release
- NAME(S)OF THE ACQUIRER AND ITS(PAC) : HDFC Mutual Fund
- Alkem Laboratories Limited has informed the Exchange about Intimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ( SEBI LODR Regulations ) - Outcome of the 52nd Annual General Meeting of the Company and Disclosure of voting results thereat. |SUBJECT: Shareholders meeting
- ALKEM LABORATORIES LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting) |SUBJECT: Shareholders meeting
- Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- ALKEM LABORATORIES LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL

### Fundamentals

Alkem Laboratories reported a sequential decline in revenue from operations for the three quarters ending Q4 FY2025-26. Revenue decreased from ₹4,009.99 crore in Q2 FY2025-26 to ₹3,736.82 crore in Q3 FY2025-26, and further to ₹3,603.32 crore in Q4 FY2025-26. This revenue trend was accompanied by a significant drop in Profit Before Tax (PBT), which fell from ₹895.83 crore in Q2 FY2025-26 to ₹781.20 crore in Q3 FY2025-26, and then sharply to ₹422.85 crore in Q4 FY2025-26. The net profit for the period, Profit Loss For Period, also showed a declining trajectory, from ₹779.11 crore in Q2 FY2025-26 to ₹653.03 crore in Q3 FY2025-26, and a substantial decrease to ₹251.11 crore in Q4 FY2025-26. Finance costs increased sequentially from ₹35.02 crore in Q2 FY2025-26 to ₹53.88 crore in Q4 FY2025-26. Other expenses also saw an increase in the latest quarter, rising to ₹1,125.96 crore in Q4 FY2025-26 from ₹968.94 crore in Q2 FY2025-26. Tax expense followed a similar pattern, increasing from ₹116.23 crore in Q2 FY2025-26 to ₹171.17 crore in Q4 FY2025-26.

Key monitoring areas include the trend in revenue from operations and the factors influencing profitability, particularly the impact of increasing finance costs and other expenses on profit margins. Investors may also wish to monitor the trajectory of tax expenses.

- Revenue from operations sequentially decreased from ₹4,009.99 crore in Q2 FY2025-26 to ₹3,603.32 crore in Q4 FY2025-26.
- Profit Before Tax (PBT) declined sequentially from ₹895.83 crore in Q2 FY2025-26 to ₹422.85 crore in Q4 FY2025-26.
- Profit Loss For Period decreased from ₹779.11 crore in Q2 FY2025-26 to ₹251.11 crore in Q4 FY2025-26.
- Finance costs increased sequentially from ₹35.02 crore in Q2 FY2025-26 to ₹53.88 crore in Q4 FY2025-26.
- Other Expenses rose to ₹1,125.96 crore in Q4 FY2025-26 from ₹968.94 crore in Q2 FY2025-26.

### Bull Case

Alkem Laboratories' stock experienced a notable increase of 2.36% on the NSE, trading at ₹5297 as of 12:49 IST. This movement occurred within a broader market context where the Nifty Pharma Index snapped a five-day losing streak, indicating potential sector-wide recovery. The company has also expanded its product offerings with the launch of NeuCeno (cenobamate) in India, a new treatment for adult epilepsy patients with partial-onset seizures. Technically, the stock's daily trend shows a bullish Supertrend indicator at ₹5041.23, and the 20-day Exponential Moving Average (EMA) at ₹5285.68 is above the 50-day Simple Moving Average (SMA) at ₹5459.43, suggesting upward momentum. The monthly trend also exhibits a bullish Supertrend at ₹4130.64.

- Alkem Laboratories' stock price rose by 2.36% to ₹5297 on the NSE as of 12:49 IST on 2026-09-18.
- The company launched NeuCeno (cenobamate) in India for epilepsy treatment in adult patients with partial-onset seizures.
- The daily technical trend shows a bullish Supertrend reading of ₹5041.23.
- The monthly technical trend indicates a bullish Supertrend at ₹4130.64.

- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Alkem Laboratories Ltd spurts 2.36%
- Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India
- Benchmarks recover after recent sell-off; Nifty ends above 23,200

### Bear Case

Alkem Laboratories' stock performance shows a cautionary trend over the past year, underperforming both the Nifty and the Nifty Pharma index. While recent news highlights a new product launch, the stock's technical indicators suggest potential headwinds. The weekly trend analysis indicates a bearish Supertrend, and the stock is trading below its 50-day Simple Moving Average (SMA). Furthermore, the company is experiencing a notable drawdown from its recent highs, indicating potential investor caution.

- The stock is down 3.33% in the last year, compared to a 8.21% drop in the NIFTY and a 17.44% drop in the Nifty Pharma index.
- The weekly trend analysis shows a bearish Supertrend at 5908.05.
- The stock is trading below its 50-day SMA of 5459.43 as of the technical summary date.
- The current drawdown for Alkem Laboratories is -0.07, with a maximum drawdown of -0.18.

- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Alkem Laboratories Ltd spurts 2.36%
- Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India
- Benchmarks recover after recent sell-off; Nifty ends above 23,200

### FAQs

**What new products has Alkem Laboratories launched recently?**

Alkem Laboratories launched NeuCeno (cenobamate) on September 16, 2026, for adult patients with partial-onset seizures. This medication is the first cenobamate available in India and is offered in strengths from 12.5 mg to 200 mg. Additionally, on September 8, 2026, the company launched Renocia ExoTM, described as India's first patented Ginsenoside Exosome-based hair growth serum, to strengthen its dermatology portfolio.

**How has Alkem Laboratories' stock performed over the past year compared to market indices?**

As of 12:49 IST on the day of the report, Alkem Laboratories Ltd was trading at ₹5297, up 2.36% for the day. However, over the last year, the stock has decreased by 3.33%. This compares to a 8.21% drop in the NIFTY and a more significant 17.44% drop in the Nifty Pharma index over the same period.

**What recent changes have occurred in Alkem Laboratories' senior management?**

Alkem Laboratories appointed Dr. Shubhadeep Sinha as Senior Vice President, effective September 15, 2026. Dr. Sinha brings over 25 years of experience in areas including clinical development, medical affairs, and regulatory affairs.

**What are the key technical support and resistance levels for Alkem Laboratories stock?**

As of September 18, 2026, key technical levels for Alkem Laboratories include immediate resistance at ₹5489.83 (0.43% higher) and support at ₹5419.17 (-0.87% lower). Further resistance is noted at ₹5502.80, while a significant support level is identified at ₹5297.00.

- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Alkem Laboratories Ltd spurts 2.36%
- Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India
- Benchmarks recover after recent sell-off; Nifty ends above 23,200
- Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.". |SUBJECT: Press Release
- ALKEM: Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the company w.e.f. September 15, 2026. |SUBJECT: Appointment
- ALKEM LABORATORIES LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA
- Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum". |SUBJECT: Press Release
- NAME(S)OF THE ACQUIRER AND ITS(PAC) : HDFC Mutual Fund
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Weak Uptrend
- Pivot point: ₹5,290.33
- Risk regime: Price Risk Currently Contained

### Support levels
- 5297
- 5199
- 5089.264453125

### Resistance levels
- 5502.796875
- 5660.169177246094
- 5674.84375

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +2.21% |
| return_10 | +5.27% |
| return_1m | -0.16% |
| return_1y | -0.24% |
| return_20 | +1.23% |
| return_3m | +1.76% |
| return_5 | +6.39% |
| return_6m | +2.15% |
| return_since_start | -1.88% |
| return_ytd | +0.05% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.21% |
| annualized_volatility | +22.65% |

## Quarterly financials

- Latest complete quarter: fy26_q4

# Rising expenses and higher taxes cut profit despite revenue growth

In the fourth quarter of FY2025–26, Alkem Laboratories reported a 14.6% year-on-year increase in revenue, but net profit fell 22.1%. The decline was driven by a sharp rise in other operating expenses, sustained growth in finance costs, and a substantially higher tax charge. Both revenue and profit also declined sequentially from the preceding quarter, with the drop in net profit particularly steep.

## Revenue and Profit Trends

Revenue from operations stood at ₹3,603.32 crore, up from ₹3,143.75 crore a year earlier and down from ₹3,736.82 crore in the prior quarter. Profit before tax came in at ₹422.85 crore, an increase of 6.7% year-on-year but a decrease of 45.9% sequentially. Net profit fell to ₹251.11 crore, marking a 22.1% year-on-year decline and a 61.5% sequential drop. The divergence between top-line growth and bottom-line contraction defines the quarter’s financial result.

## Cost Structure and Expense Growth

Total expenses, calculated as revenue plus other income minus profit before tax, amounted to ₹3,380.54 crore. The sum of five disclosed cost categories—cost of materials consumed (₹894.94 crore), employee benefit expense (₹712.10 crore), finance costs (₹53.88 crore), depreciation (₹105.76 crore), and other expenses (₹1,125.96 crore)—totalled ₹2,892.64 crore. The remaining ₹487.90 crore, representing 14.4% of total expenses, is attributable to other cost items not explicitly broken out in the company’s quarterly reporting.

Other expenses, the largest single category, rose 31.4% year-on-year and 23.1% sequentially, growing faster than revenue and directly limiting profit expansion. Finance costs have risen for five consecutive quarters, reaching ₹53.88 crore, an 89.6% increase over the prior-year quarter and a 28.0% sequential rise. Cost of materials consumed accounted for 24.8% of revenue, employee benefits for 19.8%, and depreciation for 2.9%.

## Tax Expense and Effective Tax Rate

Tax expense for the quarter was ₹171.17 crore, more than double the ₹73.33 crore recorded a year earlier and 34.1% above the prior quarter. This resulted in an effective tax rate of 40.5%, compared with 18.5% a year ago and 16.3% in Q3 FY2025–26. The year-on-year increase in tax expense totalled ₹97.84 crore, directly reducing the profit for the period.

## Earnings Per Share

Basic and diluted earnings per share were both ₹19.77, down 22.7% from ₹25.57 a year earlier and 62.8% from ₹53.19 in the preceding quarter. The movement aligns precisely with the net profit decline.

## Key Takeaway

In Q4 FY2025–26, a sharp increase in other operating expenses, rising finance costs, and an elevated effective tax rate combined to push net profit 22.1% lower year-on-year, despite a 14.6% increase in revenue. The sequential fall was even steeper, with net profit declining 61.5% from the preceding quarter. The quarter’s performance highlights how rapid expense growth and higher tax charges can offset top-line gains, resulting in a significant contraction in reported earnings.

### Ratios

## Official filings

- 2026-09-16 — Press Release: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf)
- 2026-09-15 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_15092026210812_Reg_30.pdf)
- 2026-09-15 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_13311_WebXMLFile_20260915_213337240.xml)
- 2026-09-08 — Press Release: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_08092026150801_Intimation_signed.pdf)
- 2026-09-01 — Regulatory Filing: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_09012026120359_52969.zip)
- 2026-08-27 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_27082026183137_Stockexchangeintimation_signed.pdf)
- 2026-08-20 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20260820_200656339.xml)
- 2026-08-17 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_17082026185912_Stockexchangeintimation-Signed.pdf)
- 2026-08-15 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_15082026171115_signedintimation.pdf)
- 2026-08-14 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20260814_194004063.xml)
- 2026-08-14 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_14082026190600_AlkemEarningsConferenceCallAudioRecording_August2026_Signed.pdf)
- 2026-08-14 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_14082026140121_IntimationforOpeningofTradingWindow14082026.pdf)
- 2026-08-06 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_06082026162857_Intimation_USFDA_inspection_-_OAI_classification_Signed.pdf)
- 2026-08-03 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_03082026173902_Reg30AppointmentofRajpalsingh_Signed.pdf)
- 2026-07-30 — Generic Announcement: Alkem Laboratories Limited announced the dispatch of the Notice of its 52nd Annual General Meeting (AGM) and the Annual Report for the financial year 2025-26, along with e-voting information, on July 30, 2026. The AGM will be held on August 27, 2026, via audio-visual means, with remote e-voting available from August 24 to August 26, 2026. The record date for determining eligibility for voting and dividends is August 7, 2026, and August 20, 2026, respectively. The company also noted that Tax Deducted at Source (TDS) will be applicable on dividends as per the Income Tax Act, 2025. — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_30072026150411_Newspaperintimation_Signed.pdf)
- 2026-07-30 — Official Filing: Alkem Laboratories Limited dispatched letters on July 30, 2026, providing the web-link to its Annual Report for FY 2025-26 to shareholders who have not registered their email addresses. The company's 52nd Annual General Meeting is scheduled for August 27, 2026, to be held via video conferencing. The Annual Report is also available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_30072026170935_Exchange_intimation_Signed.pdf)
- 2026-07-29 — Official Filing: Alkem Laboratories Limited has announced its 52nd Annual General Meeting (AGM) will be held on August 27, 2026, via Video Conferencing. The company also released its Annual Report for the financial year 2025-2026. The report details Alkem's strategic evolution into a diversified healthcare enterprise, expanding beyond pharmaceuticals into MedTech, biosimilars, and other high-growth segments. Key financial highlights for the year include revenue growth of 13.5% and EBITDA growth of 19.6%. The company also reported a significant international business growth of 22.5%. — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_29072026204537_Exchangeintimation_Signed.pdf)
- 2026-07-29 — Official Filing: Alkem Laboratories Limited has submitted its Business Responsibility and Sustainability Report for the financial year ended March 31, 2026, as required by SEBI regulations. The report details the company's operations, employee data, sustainability initiatives, and compliance with various environmental, social, and governance (ESG) principles. Key areas covered include governance, ethics, risk management, innovation, supply chain, energy consumption, waste management, and human capital development. The company also outlines its targets and performance related to greenhouse gas emissions reduction, energy efficiency, water stewardship, and diversity and inclusion. — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_29072026203800_Exchangeintimation_Signed.pdf)
- 2026-07-29 — Official Filing: Alkem Laboratories Limited will hold its 52nd Annual General Meeting on Thursday, August 27, 2026, at 11:00 AM in Mumbai, conducted via Video Conference or Other Audio-Visual Means. The agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, confirmation of interim dividend, declaration of final dividend, and the re-appointment of directors Mr. Sandeep Singh, Mr. Sarvesh Singh, and Ms. Madhurima Singh. The meeting will also ratify fees paid to Mr. Suresh D. Shenoy, Cost Accountant.
- 2026-07-27 — Official Filing: Alkem Laboratories Ltd. will host a conference call on August 14, 2026, at 4:30 p.m. IST to discuss its Q1FY27 financial results. The call will be attended by MD Sandeep Singh and CFO Nitin Agrawal, and hosted by Motilal Oswal Securities Ltd. The company's Q1FY27 financial results will be announced on the same day. — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_27072026142043_Intimationforconcallinvite_Signed.pdf)
- 2026-07-27 — Official Filing: Alkem Laboratories Limited will hold its Q1FY27 Earnings Call virtually on August 14, 2026, at 16:30 IST. The group meeting, intended for investors, analysts, and fund managers, will cover Q1 Results. Further details and registration links are available via the provided weblink, with dial-in numbers and contact information for Purvi Shah also disclosed.
- 2026-07-23 — Official Filing: Dr. Jitendra Singh Huda has resigned from his position as Senior Management Personnel at Alkem Laboratories Limited, effective July 23, 2026, to pursue other professional opportunities. The company has accepted his resignation and expressed appreciation for his contributions. — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_23072026131947_Regulation30-Signed.pdf)
- 2026-07-23 — Official Filing: Jitendra Singh Huda, Senior Vice President - Chronic Business at Alkem Laboratories Limited, resigned effective July 23, 2026. This change is categorized as a cessation in senior management personnel.
- 2026-07-21 — Official Filing: Alkem Laboratories Limited will hold a board meeting on August 14, 2026, to consider unaudited standalone and consolidated financial results for the quarter ended June 2026. The trading window for the company's securities will be closed from June 29, 2026, to August 16, 2026.
- 2026-07-17 — Official Filing: Alkem Laboratories Limited announced the completion of its acquisition of Occlutech Holding AG on July 17, 2026. The acquisition, initially announced on February 13, 2026, was carried out by Alkem Medtech Private Limited, a wholly owned subsidiary. Occlutech will now be a step-down subsidiary of Alkem Laboratories. The transaction amount was INR 11,000,000,000.

## News and market events

- 2026-09-17 — BUSINESS: **Quick Wrap: Nifty Pharma Index rises 1.66%** — Powered by Capital Market - Live News — [Source](https://www.business-standard.com/markets/capital-market-news/quick-wrap-nifty-pharma-index-rises-1-66-126091700943_1.html)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-17 — BUSINESS: **Alkem Laboratories Ltd spurts 2.36%** — Alkem Laboratories Ltd is quoting at Rs 5297, up 2.36% on the day as on 12:49 IST on the NSE. The stock is down 3.33% in last one year as compared to a 8.21% drop in NIFTY and a 17.44% drop in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/alkem-laboratories-ltd-spurts-2-36-126091700511_1.html)
- 2026-09-16 — The Hindu: **Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India** — Alkem Laboratories has launched NeuCeno (cenobamate) in India for adult patients with partial-onset seizures, available in strengths from 12.5 mg to 200 mg. — [Source](https://www.thehindubusinessline.com/companies/alkem-laboratories-launches-neuceno-for-partial-onset-seizures-in-adults/article71473899.ece)
- 2026-09-16 — BUSINESS: **Benchmarks recover after recent sell-off; Nifty ends above 23,200** — The key equity benchmarks ended higher on Wednesday, snapping a two-session losing streak. Gains followed a pause in crude oil prices and a marginal easing in global bond yields. — [Source](https://www.business-standard.com/markets/capital-market-news/benchmarks-recover-after-recent-sell-off-nifty-ends-above-23-200-126091600881_1.html)
- 2026-09-16 — BUSINESS: **Indices snap 2-day losses; FMCG shares rally** — As per provisional closing data, the barometer index, the S&P BSE Sensex jumped 332.63 points or 0.45% to 74,336.45. The Nifty 50 index added 99 points or 0.43% to 23,217.60. In the past two consecutive trading sessions the Sensex and Nifty declined 1.20% and 1.53%, respectively. — [Source](https://www.business-standard.com/markets/capital-market-news/indices-snap-2-day-losses-fmcg-shares-rally-126091600763_1.html)
- 2026-09-16 — BUSINESS: **Nifty holds above 23,250 level; European shares trade mostly in green** — The benchmark indices traded near the day's high in afternoon trade, tracking positive cues from Asian markets as the recent rally in crude oil prices paused. Investors remained cautious ahead of the US Federal Reserves policy meeting later today. The Nifty surged above the 23,250 mark, indicating some recovery in market sentiment. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-holds-above-23-250-level-european-shares-trade-mostly-in-green-126091600540_1.html)
- 2026-09-16 — BUSINESS: **Alkem Labs launches epilepsy management drug Cenobamate in India** — Alkem Laboratories has announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. — [Source](https://www.business-standard.com/markets/capital-market-news/alkem-labs-launches-epilepsy-management-drug-cenobamate-in-india-126091600477_1.html)
- 2026-09-08 — CNBC-TV18: **Alkem launches India’s first patented ginsenoside exosome-based hair growth serum** — Alkem Laboratories has launched Renocia Exo™, a hair regeneration serum combining ginsenoside phyto-exosomes, biomimetic peptides, copper peptides and stem cell-supportive actives. — [Source](https://www.cnbctv18.com/business/companies/alkem-launches-indias-first-patented-ginsenoside-exosome-based-hair-growth-serum-19986670.htm)
- 2026-09-01 — The Hindu: **Broker’s Call: Alkem Laboratories (Buy)** — Elara Securities — [Source](https://www.thehindubusinessline.com/markets/brokers-call-alkem-laboratories-buy/article71414475.ece)
- 2026-08-18 — BUSINESS: **Volumes spurt at Billionbrains Garage Ventures Ltd counter** — Billionbrains Garage Ventures Ltd notched up volume of 819.05 lakh shares by 10:46 IST on BSE, a 44.78 fold spurt over two-week average daily volume of 18.29 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-billionbrains-garage-ventures-ltd-counter-126081800352_1.html)
- 2026-08-17 — CNBC-TV18: **Five reasons behind Investec's upgrade of Alkem Labs, and why JPMorgan is cautious** — 60% of the analysts who have coverage on Alkem Laboratories have a "buy" recommendation, while the rest are either "neutral" or have a "sell" rating on the stock. — [Source](https://www.cnbctv18.com/market/alkem-labs-share-price-investec-upgrade-q1-results-key-factors-macquarie-jpm-cautious-buy-sell-19970590.htm)
- 2026-08-17 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: GIFT Nifty trades 50 pts lower; M&M in focus** — Stock Market Live Updates: The Nifty has been grinding lower even as it consolidates in a narrow range. The index has lost 300 points in the last six sessions, despite a better-than-expected earnings season. Oil prices remain near $90 a barrel. Watch for movements on the USD-INR and further block deal announcements. Watch this space for all the LIVE stock market updates, management commentary and stocks in news. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-reliance-hdfc-bank-cochin-nmdc-voltas-gmr-jupiter-share-price-liveblog-19970547.htm)
- 2026-08-14 — The Hindu: **Q1 Results Today Live: BDL, Ashok Leyland, 3M India Q1 PAT rise y-o-y, Electrotherm, NATCO Pharma, Alkem Lab PAT decline, NMDC, Voltas, Cochin Shipyard, Physicswallah, PTC Ind, Borosil to announce Q1 results** — Q1 Results Today, 14th August 2026 Live Updates:  Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-ashok-leylad-nmdc-alkem-lab-bharat-dynamics-voltas-3m-india-cochin-shipyard-physicswallah-cholamandalam-fin-ptc-ind-natco-pharma-tmpv-results-14-august-2026/article71340415.ece)
- 2026-08-14 — The Hindu: **Sensex today | Stock Market Live: Sensex off day's low, down 118 pts; Nifty below 24,400 as West Asia worries weigh** — Sensex, Nifty, Share Prices LIVE:  Indian equities remained subdued in noon trade on Friday, with persistent West Asia tensions and continued foreign selling weighing on sentiment. Easing expectations of a September US Fed rate hike and softer crude prices offered limited support, restricting the market’s decline. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-14th-august-2026/article71341547.ece)
- 2026-08-14 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty Auto down about 140 points; Tata Motors PV leads loses** — Sensex Today | Stock Market LIVE Updates: We are the half way mark of the day's trade and the markets remain in red. The markets are under pressure, with the Nifty index falling towards the 24,300 mark. The Nifty Bank is also trading on similar ground, falling below the 57,500 mark. Tata Motors PV, Hindalco, Max Health are the top losers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-sensex-hdfc-bank-nifty-bank-q1-earnings-tata-motors-max-fin-defence-bdl-share-price-liveblog-19969121.htm)
- 2026-08-14 — CNBC-TV18: **Alkem Labs Q1 Results: Shares down 3% after profit falls; revenue rises 11%** — Alkem Laboratories MD Sandeep Singh said the company had started FY27 on a steady note, with healthy growth across its India and international businesses. He said the India business continued to outperform the market, while growth in non-US international markets remained encouraging. — [Source](https://www.cnbctv18.com/market/alkem-labs-q1-results-shares-down-profit-falls-revenue-rises-india-business-non-us-international-markets-19969594.htm)
- 2026-08-07 — MONEYCONTROL: **business news live today on August 7 corporate news AGM Q1 results IPO updates** — business news live today on August 7, corporate news, AGM, Q1 results, IPO updates — [Source](https://www.moneycontrol.com/news/business/business-news-live-today-on-august-7-corporate-news-agm-q1-results-ipo-updates-liveblog-13997112.html)
- 2026-08-07 — BUSINESSTODAY: **Top stocks in news: LIC, Britannia, TVS Motor, Premier, Dabur, Apollo Tyres, Alkem Labs** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, LIC of India, Britannia Industries, TVS Motor Company, Premier Energies, Dabur India, Apollo Tyres, Siemens Energy India, Alkem Laboratories, J Kumar Infraprojects, Life Insurance Corporation of India, Kirloskar Oil Engines, Shipping Corporation of India, Vijaya Diagnostic Centre, Aegis Logistics, Aegis Vopak Terminals — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-lic-britannia-tvs-motor-premier-dabur-apollo-tyres-alkem-labs-547804-2026-08-07)
- 2026-08-07 — Mint: **Stocks to watch: SBI, Ola Electric, LIC among shares in focus today; check list here** — Stock market today: Gift Nifty was trading near the 24,657 mark, down over 82 points from the previous close of Nifty futures. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-watch-sbi-ola-electric-lic-among-shares-in-focus-today-check-list-here-11786066835314.html)
- 2026-08-07 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: GIFT Nifty 90 pts lower; Jefferies raises target for Premier Eng** — Sensex Today | Stock Market Live Updates: The index holding on to 24,500 levels on the downside is something that the bulls will be pleased with as analysts believe it is forming a base for a move, first towards 24,800, and eventually to record levels. Crude oil prices though, have staged a minor rebound overnight with brent returning to above $80 a barrel. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-cas-tata-hero-pgel-lic-sci-sbi-ncc-premier-crompton-midcaps-share-price-liveblog-19963799.htm)
- 2026-08-07 — The Hindu: **Stocks to watch, Aug 7: HUDCO, REC, PFC, IRFC, RailTel, Bondada, Aegis Logistics, Alkem Lab, J Kumar Infra, TVS Motor Co** — Key market players face increased regulatory scrutiny as the RBI classifies four state-owned NBFCs, while RailTel and Aegis Logistics secure major contracts, and TVS Motor enters the African electric vehicle market. — [Source](https://www.thehindubusinessline.com/markets/stocks-to-watch-aug-7-hudco-rec-pfc-irfc-railtel-bondada-aegis-logistics-alkem-lab-j-kumar-infra-tvs-motor-co/article71316098.ece)
- 2026-08-07 — MONEYCONTROL: **Stocks to Watch Today: Alkem Labs, J Kumar Infra, Dabur, Britannia, Siemens Energy, Shipping Corporation, Vijaya Diagnostic Centre in focus on 7 August** — Stocks to watch, stocks in focus today, stocks in focus, share market today, top stocks, shares in focus today, shares today, today stocks to watch, trending stocks, trending stocks today, markets today, buzzing stocks, stocks today, stock market today,Britannia Industries,Siemens Energy India,Life Insurance Corporation of India,Shipping Corporation of India,Vijaya Diagnostic Centre,Apollo Tyres,Premier Energies,Alkem Laboratories,J Kumar Infraprojects,Aegis Logistics,Aegis Vopak Terminals,Dabur India,Neuland Laboratories,Orient Electric,Shadowfax Technologies,KPIT Technologies,CreditAccess Grameen,Indegene,Bandhan Bank — [Source](https://www.moneycontrol.com/news/business/markets/stocks-to-watch-today-alkem-labs-j-kumar-infra-dabur-britannia-siemens-energy-shipping-corporation-vijaya-diagnostic-centre-in-focus-on-7-august-13997019.html)
- 2026-08-06 — CNBC-TV18: **Alkem Laboratories’ Daman facility gets US FDA OAI classification after seven observations** — Shares of Alkem Laboratories Ltd ended at ₹5,609.00, down by ₹53.75, or 0.95%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/alkem-laboratories-share-price-daman-facility-gets-us-fda-oai-classification-after-seven-observations-19963765.htm)

## Business profile

**Strategic vision:** Multinational pharmaceutical company developing, manufacturing, and selling pharmaceutical products.

### Business segments
- **Prescription Products (Rx):** Focuses on branded generic formulations across various acute and chronic therapeutic areas.
- **Alkem Generics:** A trade generics division catering to domestic market segments, comprising sub-divisions such as Futura, Maxxio, and Novokem.
- **Active Pharmaceutical Ingredients (APIs):** Handled by the Alkem Activa division, which synthesizes APIs for captive consumption and commercial supply.
- **Biosimilars and MedTech:** Develops biosimilars through its subsidiary Enzene Biosciences, alongside medical technology solutions in cardiology and orthopedics.

### Competitive strengths
- Integrated operations across R&D, API synthesis, formulation manufacturing, and distribution.
- Diversified business model balancing domestic and international markets.
- Strong presence in key therapeutic segments.
- Regulatory compliance with global agencies.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%
- [ASTERDM (Healthcare)](https://faxioms.com/stocks/asterdm) — -0.85%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/alkem
Markdown representation: https://faxioms.com/stocks/alkem?render=md